Introduction
Transdermal drug delivery offers a painless alternative to traditional injections, yet it faces a significant hurdle: the stratum corneum. This outermost layer of skin acts as a barrier to large or hydrophilic molecules. Microneedles provide a solution by creating microchannels for drug transport without reaching deep-seated nerves. However, traditional silicon microneedles are brittle. When they break during insertion, non-biodegradable crystalline silicon fragments remain in the skin, posing risks of inflammation and infection.
Fabrication Methodology
To address the safety concerns of silicon breakage, researchers developed a hybrid microneedle array featuring biodegradable tips. The fabrication involves a two-stage process:
- Shaping the Array: Using Reactive Ion Etching (RIE) with an $SF_6/O_2$ plasma, the needles are carved from a silicon wafer. Techniques such as photoresist reflow and the "notching effect"—where reflected ions enhance etching beneath the mask—are employed to achieve sharp, high-aspect-ratio profiles.
- Selective Anodization: The needle bodies are protected with a Silicon Nitride ($Si_3N_4$) layer, leaving only the tips exposed. Electrochemical anodization in a hydrofluoric acid solution then converts the crystalline silicon at the tip into porous silicon. Unlike its crystalline counterpart, porous silicon is bioactive and biodegrades within the body over 2 to 3 weeks.
Performance and Safety
The resulting needles range from 50 $\mu m$ to 150 $\mu m$ in length, optimized to penetrate the epidermis while avoiding pain receptors. In tests using a pig skin model, these arrays demonstrated a five-fold increase in the delivery rate of calcein compared to passive diffusion.
The "safe-to-fail" design ensures that if a tip breaks off during application, it will safely dissolve in the skin. This approach leverages the material properties of porous silicon to transform a mechanical failure into a harmless biological process.
Conclusion
This hybrid design successfully combines the structural advantages of silicon MEMS fabrication with the safety of biodegradable materials. Future research will focus on long-term stability and in vivo trials to validate the technology for clinical use with therapeutics like insulin or vaccines.
Summary updated